Claims
- 1. A method of treating anxiety in animals, including humans, by administering an effective amount of a compound selected from the group having the formula: ##STR24## wherein: Ar is pyridyl in any of its positions optionally substituted by halo, phenyl or phenyl substituted by 1 or 2 groups selected from chloro, bromo, iodo, fluoro, loweralkyl, loweralkoxy, nitro, aminocarbonyl, or trifluoromethyl;
- B is oxygen or sulfur;
- Z is oxygen or sulfur;
- R.sup.1 and R.sup.2 may be the same or different and are selected from hydrogen, loweralkyl, phenyl, phenyl substituted by halo, loweralkyl, loweralkoxy, nitro, cyano, trifluoromethyl, carbomethoxy or carboethoxy; allyl, substituted allyl, propargyl, cycloalkyl (3-9C), loweralkylcycloalkyl, cycloalkylloweralkyl, arylloweralkyl wherein aryl is phenyl or phenyl substituted by halo, loweralkyl, loweralkoxy, nitro, cyano, trifluoromethyl, carbomethoxy, or carboethoxy; and diloweralkylaminoloweralkyl, and R.sup.1 and R.sup.2 when taken together with the adjacent nitrogen atom may form a heterocyclic amino group selected from azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, imidazolyl, piperazinyl, (halophenyl) piperidin-yl, phenyl-1,2,3,6-tetrahydropyridin-1-yl, phenylpiperidin-1-yl, hydroxypiperidin-1-yl, 4-morpholino, 4-(3,5-diloweralkyl)morpholino, 1,2,3,6-tetrahydropyridin-1-yl, (halophenyl)(hydroxy)piperidin-1-yl, 4-(2,6-diloweralkyl)morpholino, pyrrolo[1,2-a]pyrazin-2-yl, homopiperazinyl, 4-substituted piperazinyl, and 4-substituted homopiperazinyl;
- R.sup.3 is selected from hydrogen, loweralkyl, aryl or arylloweralkyl wherein aryl or the aryl moiety is phenyl or phenyl substituted by halo, loweralkyl, loweralkoxy, nitro, cyano, trifluoromethyl, carbomethoxy or carboethoxy; the geometrical isomers including cis, trans, (E) and (Z) isomers thereof, and the pharmaceutically acceptable acid addition salts thereof when R.sup.1 and R.sup.2 have one or more salt-forming basic amino groups, or Ar is pyridyl, and the hydrates thereof.
- 2. A method according to claim 1 wherein the compound used is 3-[3-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide.
- 3. A method according to claim 1 wherein the compound used is N-ethyl-3-[3-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide.
- 4. A method according to claim 1 wherein the compound used is N-cyclopropyl-3-[3-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide.
- 5. A method according to claim 1 wherein the compound used is N-propyl-3-[4-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide.
- 6. A method according to claim 1 wherein the compound used is N-(2-propenyl)-3-[4-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide.
- 7. A method according to claim 1 wherein the compound used is N-cyclopropyl-3-[4-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide.
- 8. A method according to claim 1 wherein the compound used is N-(2-propynyl)-3-[4-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide.
- 9. A method according to claim 1 wherein the compound used is N-(1-methylethyl)-3-[4-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide.
- 10. A method according to claim 1 wherein the compound used is trans-N,2-dimethyl-3-[3-trifluoromethyl)phenoxy]-1-azetidinecarboxamide.
- 11. A method according to claim 1 wherein the compound used is 3-(3-chlorophenoxy)-N-(2-propenyl)-1-azetidinecarboxamide.
- 12. A method according to claim 1 wherein the compound used is 3-(4-fluorophenoxy)-1-azetidinecarboxamide.
- 13. A method according to claim 1 wherein the compound used is 3-(4-fluorophenoxy)-N-(2-propenyl)-1-azetidinecarboxamide.
- 14. A method according to claim 1 wherein the compound used is 3-(4-chlorophenoxy)-1-azetidinecarboxamide.
- 15. A method according to claim 1 wherein the compound used is 3-(4-chlorophenoxy)-N-methyl-1-azetidinecarboxamide.
- 16. A method according to claim 1 wherein the compound used is 3-(4-chlorophenoxy)-N-(2-propenyl)-1-azetidinecarboxamide.
- 17. A method according to claim 1 wherein the compound used is 3-(3-methylphenoxy)-N-(2-propenyl)-1-azetidinecarboxamide.
Parent Case Info
This is a division of application Ser. No. 06/921,521, filed Oct. 22, 1986, now U.S. Pat. No. 5,068,231 which is a continuation-in-part application of copending U.S. patent application Ser. No. 706,632 filed Feb. 28, 1985 now abandoned.
US Referenced Citations (5)
Foreign Referenced Citations (1)
Number |
Date |
Country |
102194A |
Mar 1984 |
EPX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
921521 |
Oct 1986 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
706632 |
Feb 1985 |
|